Clear cell renal carcinoma
Therapeutic area
Oncology
Rare disease
Yes
- Definition
- A malignant epithelial neoplasm of the kidney characterized by the presence of lipid-containing clear cells within a vascular network. The tumor may metastasize to unusual sites and late metastasis is common.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Clear cell renal carcinoma
- Therapeutic area
- Oncology
- clear cell renal carcinoma
- Grawitz tumor
- Grawitz tumour
- RCC, clear cell adenocarcinoma
- clear cell adenocarcinoma of kidney
- clear cell adenocarcinoma of the kidney
- clear cell adenocarcinoma, kidney
- clear cell carcinoma of kidney
- clear cell carcinoma of the kidney
- clear cell renal cell cancer
- clear cell renal cell carcinoma
- conventional (clear cell) renal cell adenocarcinoma
- conventional (clear cell) renal cell carcinoma
- conventional renal cell carcinoma
- kidney clear cell adenocarcinoma
- kidney clear cell carcinoma
- renal cell carcinoma, clear cell adenocarcinoma
- renal clear cell adenocarcinoma
- renal clear cell carcinoma
- clear-cell metastatic renal cell carcinoma
- hypernephroma
- Severity
- Severe
- Nephrology
- Oncology
- MONDO ID
- MONDO:0005005
- Parent condition
- MONDO:0005004
Related records
Broader conditions (23)
- Adenocarcinoma
- Cancer
- Cancer or benign tumor
- Carcinoma
- Clear cell adenocarcinoma
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Epithelial neoplasm
- Glandular cell neoplasm
- Human disease
- Kidney cancer
- Kidney disorder
- Kidney neoplasm
- Malignant urinary system neoplasm
- Neoplasm
- Neoplastic disease or syndrome
- Nonpapillary renal cell carcinoma
- Renal carcinoma
- Renal cell adenocarcinoma
Narrower conditions (2)
- Hereditary clear cell renal cell carcinoma
- Multilocular clear cell renal cell carcinoma
Trials (268)
- [18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma
- [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma
- 177LuPSMA in Renal Cell Carcinoma
- 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
- 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC
- 68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma
- 68Ga-NY104 PET/CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses
- 68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.
- 68Ga-NY104 PET/CT in Patients With Metastasis/Recurrence Clear Cell Renal Cell Carcinoma Suspicion
- 68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma
- 68Ga-NYM096 PET/ CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses
- 68Ga-NYM096/177Lu-NYM096 in Metastatic ccRCC
- 68Ga-P16-093 and 18F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma Patients
- 89Zr-DFO-girentuximab Expanded Access Program (EAP)
- 89Zr-girentuximab ) Dosimetry in CCRC Study - ZIR-DOSE
- 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
- 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study
- A Beta-only IL-2 ImmunoTherapY Study
- A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
- A Clinical Research of CD70-targeted CAR-NKT Cells (CGC738) Therapy in RCC
Approved drugs (13)
- Axitinib
- Belzutifan
- Bevacizumab
- Cabozantinib S-malate
- Everolimus
- Ipilimumab
- Nivolumab
- Pazopanib hydrochloride
- Pembrolizumab
- Sorafenib tosylate
- Sunitinib
- Sunitinib malate
- Temsirolimus
Drugs in development (55)
- Abemaciclib Phase 1
- Adavosertib Phase 2
- AGS-16C3F Phase 2
- Aldesleukin Phase 3
- Alovudine F-18 Phase 1
- Ascorbic acid Phase 2
- Avelumab Phase 3
- Batiraxcept Phase 1
- Cabozantinib Phase 3
- Cadonilimab Phase 2
- Camrelizumab Phase 2
- Carotuximab Phase 2
- Catequentinib Phase 2
- Cediranib maleate Phase 2
- Cyclophosphamide Phase 3
- Daratumumab Early phase 1
- Dovitinib Phase 3
- Durvalumab Phase 3
- Entinostat Phase 2
- Enzalutamide Early phase 1